Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy.

Cohen EE, Ahmed O, Kocherginsky M, Shustakova G, Kistner-Griffin E, Salama JK, Yefremenko V, Novosad V.

Oral Oncol. 2013 Oct;49(10):1025-31. doi: 10.1016/j.oraloncology.2013.07.009. Epub 2013 Aug 27.

2.

Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.

Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE.

J Geriatr Oncol. 2013 Oct;4(4):327-33. doi: 10.1016/j.jgo.2013.05.003. Epub 2013 Jun 10.

3.

Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.

Gouvêa de Lima A, Villar RC, de Castro G Jr, Antequera R, Gil E, Rosalmeida MC, Federico MH, Snitcovsky IM.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):270-5. doi: 10.1016/j.ijrobp.2010.10.012. Epub 2010 Dec 14.

PMID:
21163585
4.

L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.

Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H, Uejima E, Ito T.

Oncol Rep. 2015 Jan;33(1):33-9. doi: 10.3892/or.2014.3564. Epub 2014 Oct 23.

5.

Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.

Yokota T, Onoe T, Ogawa H, Hamauchi S, Iida Y, Kamijo T, Suda T, Yurikusa T, Nishimura T, Yasui H, Onitsuka T.

Jpn J Clin Oncol. 2015 Feb;45(2):183-8. doi: 10.1093/jjco/hyu196. Epub 2014 Nov 23.

PMID:
25420692
6.

Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.

Sakashita T, Homma A, Hatakeyama H, Furusawa J, Kano S, Mizumachi T, Iizuka S, Onimaru R, Tsuchiya K, Yasuda K, Shirato H, Fukuda S.

Acta Otolaryngol. 2015 Aug;135(8):853-8. doi: 10.3109/00016489.2015.1030772. Epub 2015 Mar 26.

PMID:
25814008
7.

Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.

Acevedo-Henao CM, Valette G, Miglierini P, Lefur E, Pradier O.

Cancer Radiother. 2012 Oct;16(7):601-3. doi: 10.1016/j.canrad.2012.06.005. Epub 2012 Oct 22.

PMID:
23089070
8.

[Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy].

Zhang XX, Ma L, Wang JL, Wu WM, Feng LC, Huang DL.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Jun;46(6):505-8. Chinese.

PMID:
21924104
9.

Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, Hayes N, Weiss J, Grilley-Olson J, Zanation A, Hackman T, Funkhouser W, Sheets N, Weissler M, Mendenhall W.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):976-85. doi: 10.1016/j.ijrobp.2015.08.033. Epub 2015 Aug 22.

PMID:
26581135
10.

Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.

Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB.

Cancer. 2009 Oct 1;115(19):4514-23. doi: 10.1002/cncr.24525.

11.

Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.

Daly ME, Lau DH, Farwell DG, Luu Q, Donald PJ, Chen AM.

Am J Otolaryngol. 2013 Nov-Dec;34(6):631-5. doi: 10.1016/j.amjoto.2013.07.010. Epub 2013 Aug 15.

PMID:
23954137
12.

Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.

Inohara H, Takenaka Y, Yoshii T, Nakahara S, Yamamoto Y, Tomiyama Y, Seo Y, Isohashi F, Suzuki O, Yoshioka Y, Sumida I, Ogawa K.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):934-41. doi: 10.1016/j.ijrobp.2014.12.032.

PMID:
25832686
13.

Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.

Fukada J, Shigematsu N, Takeda A, Ohashi T, Tomita T, Shiotani A, Kunieda E, Kawaguchi O, Fujii M, Kubo A.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):417-24. doi: 10.1016/j.ijrobp.2009.01.056. Epub 2009 May 4.

PMID:
19409727
14.

Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.

Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H.

Jpn J Clin Oncol. 2015 Dec;45(12):1116-21. doi: 10.1093/jjco/hyv142. Epub 2015 Sep 29.

PMID:
26423341
15.

Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Semrau R, Temming S, Preuss SF, Klubmann JP, Guntinas-Lichius O, Müller RP.

Strahlenther Onkol. 2011 Oct;187(10):645-50. doi: 10.1007/s00066-011-1111-7. Epub 2011 Sep 23.

PMID:
21947123
16.

Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A.

Oncol Rep. 2003 Jan-Feb;10(1):197-206.

PMID:
12469169
17.

Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.

Rades D, Ulbricht T, Hakim SG, Schild SE.

Strahlenther Onkol. 2012 Jan;188(1):42-8. doi: 10.1007/s00066-011-0005-z. Epub 2011 Dec 24.

PMID:
22194029
18.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE, Meredith RF, Berger D, Chen MG, Mendenhall W.

J Clin Oncol. 2008 May 20;26(15):2489-96. doi: 10.1200/JCO.2007.13.7349.

PMID:
18487568
19.

Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.

Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J, Fan CY, Breau R, Suen J.

Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):861-7.

PMID:
15262764
20.

Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.

Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT.

Am J Clin Oncol. 2010 Apr;33(2):144-7. doi: 10.1097/COC.0b013e3181979093.

PMID:
19786848

Supplemental Content

Support Center